Abstract: A transdermal delivery system for delivery of a triptan into a tissue membrane of a subject. The system includes a transdermal microporation apparatus for heating a skin surface and a triptan drug delivery patch. The drug delivery patch comprises a top layer comprising an adhesive, a middle layer comprising the triptan, and a bottom layer. A method for treating a subject comprises identifying a subject having a migraine, using the transdermal microporation apparatus to open a plurality of micropores in the skin of the subject, and applying the triptan drug delivery patch to the subject's skin over the micropores for a period of time effective to deliver the triptan through the micropores in an amount effective to treat the subject's migraine.
Abstract: A method of extracting a Rhodiola plant comprising the steps of harvesting and drying the plant; extracting the alkaloids from the plant in a solvent; filtering the solvent-Rhodiola plant mixture to remove the solvent and extracted alkaloids from a spent plant matter; drying the spent plant matter; purifying and separating the extracted alkaloids from the solvent; and mixing the purified alkaloids back into the dried spent plant matter. Also, products of the method include vaporizing liquids, medicinal compositions, kief compositions, rolling papers, and filters for tobacco and vaporizing equipment comprising the mixture of the purified alkaloids and the dried spent plant matter produced according to the method. Further disclosed is a Rhodiola plant having approximately 1.3-8.57% total phenolic compounds containing 1-3.5% salidrosides and 0.03-3.6% Rosavins.
Abstract: Methods for inoculating a grain suitable for use in testing methods of reducing bacterial load are disclosed. Also disclosed are methods of reducing bacterial load on a grain by using elevated temperature and an organic acid. Also disclosed are methods of tempering a grain at an elevated temperature and reduced time as compared to standard tempering methods.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
April 25, 2023
Assignee:
General Mills, Inc.
Inventors:
David J Domingues, Steven R Pretzel, Yuewei Hu, Craig A Dowd, James P Michaels
Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.
Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
April 18, 2023
Assignee:
Endeavor Biomedicines, Inc.
Inventors:
Miguel de los Rios, John Hood, Anita Difrancesco
Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.
Type:
Grant
Filed:
October 20, 2020
Date of Patent:
April 18, 2023
Assignee:
Celgene Corporation
Inventors:
Preethi Janardhanan, Shailaja Kasibhatla, Antonia Lopez-Girona, Michael Pourdehnad
Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.
Type:
Grant
Filed:
March 4, 2022
Date of Patent:
April 18, 2023
Assignee:
Epalex Corporation
Inventors:
Steven L. Krill, Feng-Jing Chen, Michael A. Rogawski, Edward Brendan Magrab, Allen H. Heller
Abstract: The invention provides compositions and methods for preserving, restoring, or enhancing vision of a subject by administering compositions to an injured or diseased eye.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
April 11, 2023
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
Abstract: The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin.
Abstract: A composition is produced by a method of extracting a Kanna plant, wherein the method comprises the steps of harvesting and drying the plant, extracting the alkaloids comprising Mesembrine from the plant in a solvent, and filtering the solvent-Kanna plant mixture to remove the solvent and extracted alkaloids from a spent Kanna plant matter. The method further includes drying the spent Kanna plant matter, purifying and separating the extracted alkaloids from the solvent, and mixing the extracted alkaloids back into the dried spent plant matter.
Abstract: The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
Abstract: Disclosed herein is a chemical delivery system having: i) a cargo compound comprising a first reactive moiety covalently bonded to a first enrichment moiety and a tethered cargo moiety, wherein the first reactive moiety is bonded to the tethered cargo moiety via a cleavable linker; and ii) a trigger compound comprising a second reactive moiety covalently bonded to a second enrichment moiety and a cargo-releasing moiety. The first enrichment moiety and the second enrichment moiety cause an increase in concentration of the cargo compound and the concentration of the trigger compound at a target site, causing a bimolecular reaction between the first reactive moiety and the second reactive moiety to form a cyclization precursor compound. The cargo moiety is then released from the cyclization precursor compound in a unimolecular cyclization reaction. Methods for treating conditions such as cancer, inflammatory conditions, and infections with the chemical delivery systems are also described.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
March 21, 2023
Assignee:
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Inventors:
Binghe Wang, Yueqin Zheng, Xingyue Ji, Robert Emuobonuvie Aghoghovbia
Abstract: Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage.
Type:
Grant
Filed:
January 2, 2019
Date of Patent:
March 14, 2023
Assignee:
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Abstract: The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.
Abstract: Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R1-R14, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.
Type:
Grant
Filed:
July 17, 2020
Date of Patent:
March 7, 2023
Assignee:
TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Salim Merali, Carlos A. Barrero, Wayne E. Childers, George C. Morton
Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
March 7, 2023
Assignee:
Mind Medicine, Inc
Inventors:
Scott Freeman, Stots B. Reele, Jeanne Bonelle